Updates to the Spectrum/AIM model for the UNAIDS 2020 HIV estimates

The Spectrum/AIM model is used by national HIV programs and UNAIDS to prepare annual estimates of key HIV indicators. This article describes key updates to paediatric and adult models for the 2021 round of HIV estimates.

[1]  C. H. Dao Ostinelli,et al.  International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012–2019 , 2020, BMJ Open.

[2]  R. Glaubius,et al.  The Estimation and Projection Package Age-Sex Model and the r-hybrid model: new tools for estimating HIV incidence trends in sub-Saharan Africa , 2019, AIDS.

[3]  C. Yiannoutsos,et al.  Updates to the Spectrum/AIM model for estimating key HIV indicators at national and subnational levels , 2019, AIDS.

[4]  R. Glaubius,et al.  Estimating and projecting the number of new HIV diagnoses and incidence in Spectrum's case surveillance and vital registration tool , 2019, AIDS.

[5]  L. Myer,et al.  Integration of postpartum healthcare services for HIV-infected women and their infants in South Africa: A randomised controlled trial , 2018, PLoS medicine.

[6]  T. Brown,et al.  Updates to the Spectrum/Estimations and Projections Package model for estimating trends and current values for key HIV indicators , 2017, AIDS.

[7]  S. Vermund,et al.  Mobility and Clinic Switching Among Postpartum Women Considered Lost to HIV Care in South Africa , 2017, Journal of acquired immune deficiency syndromes.

[8]  H. Tweya,et al.  Understanding factors, outcomes and reasons for loss to follow‐up among women in Option B+ PMTCT programme in Lilongwe, Malawi , 2014, Tropical medicine & international health : TM & IH.

[9]  D. Podzamczer,et al.  Short-Term and Long-Term Clinical and Immunological Consequences of Stopping Antiretroviral Therapy in HIV-Infected Patients with Preserved Immune Function , 2013, Antiviral therapy.

[10]  Kara Wools-Kaloustian,et al.  Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. , 2012, International journal of epidemiology.

[11]  D. Havlir,et al.  Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. , 2007, The Journal of infectious diseases.

[12]  A. Verbon,et al.  Effects of Active Treatment Discontinuation in Patients With a CD4+ T-Cell Nadir Greater Than 350 Cells/mm3: 48-Week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN) , 2007, Journal of acquired immune deficiency syndromes.

[13]  Lidia Ruiz,et al.  Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients , 2007, AIDS.

[14]  N. Pantazis,et al.  Highly Active Antiretroviral Therapy Interruption: Predictors and Virological and Immunologic Consequences , 2006, Journal of acquired immune deficiency syndromes.

[15]  H. P. Study.  Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children , 2006, AIDS.

[16]  P. Ghys,et al.  © Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2004 , 2004 .

[17]  D. Dunn.  Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis , 2003, The Lancet.